
Opinion|Videos|May 6, 2024 (Updated: May 6, 2024)
Apolipoprotein E4 in Alzheimer’s Disease
Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following question(s):
- How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
- What are known risk factors for Alzheimer's disease?
- Contribution of ApoE gene polymorphism and copy numbers
- When do patients with Alzheimer’s typically present to the clinic?
- What are known risk factors for Alzheimer's disease?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
5



















